Not pretty, but then, you already know that. Rising off the mid-month low is something to be happy about, I guess.
Here's where we stand year to date:
I've noted previously the correlation between the declines in Gilead Sciences (GILD - Get Report) and the broader biotech sector. April broke that trend, which is an encouraging sign that investors are perhaps starting to differentiate between quality stocks and over-valued garbage.
Must Read: Endocyte Falls on Ovarian Cancer Drug Blowup
The April performance of big-cap biotech stocks:
05/19/15 - 04:42 PM EDT
05/19/15 - 12:48 PM EDT
05/18/15 - 08:06 AM EDT
05/05/15 - 02:43 PM EDT
05/05/15 - 10:40 AM EDT
10/09/15 - 08:50 AM EDT
10/09/15 - 08:35 AM EDT
10/09/15 - 08:31 AM EDT
10/08/15 - 12:49 PM EDT
10/08/15 - 11:24 AM EDT
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.
Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.